Clovis Plans Rucaparib Commercial Launch, After Abandoning Rociletinib
This article was originally published in The Pink Sheet Daily
In light of FDA’s plan to issue a complete response letter, Clovis ends development of next-gen EGFR inhibitor rociletinib to save cash and refocuses on approval and launch of PARP inhibitor rucaparib for ovarian cancer.
You may also be interested in...
Modeling can better inform candidate and dose selection, and support novel endpoints, labeling and postmarketing safety, even though it means stepping off the beaten path for drug development, participants say at US FDA's inaugural workshop on model-informed drug development under PDUFA VI.
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.